Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.15 USD | -2.28% | -10.87% | -25.12% |
Mar. 13 | UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating | MT |
Mar. 11 | H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.12% | 559M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |
- Stock
- Equities
- Stock ALX Oncology Holdings Inc. - Nasdaq
- News ALX Oncology Holdings Inc.
- ALX Oncology : to Collaborate With Lilly on Combination Therapy for Gastric Cancer, Gastroesophageal Junction Cancer